Vaccines are a key solution to healthcare system sustainability and disease reduction
Traditionally vaccines can take years to development.
As the COVID pandemic taught us, if we move faster, millions of lives could have been saved and trillions of dollars of economic damage could have been averted.
OUR MISSION
To unlock the potential of vaccinia as a versatile vaccine platform that can be rapidly pivoted to address new and emerging diseases and to treat and prevent complex disease with no current solutions.
SCV Vaccine Platform – a competitively differentiated solution
Safe & Immunogenic
Builds on the established safety and efficacy of vaccinia as a viral vector vaccine.
Speed
Designed as a platform technology to enable rapid new vaccine development.
Positioned as an alternative to mRNA technology for pandemic preparedness.
Scale
Advanced manufacturing technology, designed to enable responsive, high-capacity and large-scale production.
A first for viral vector manufacturing.
Plug & Play
Platform viral vector designed to enable “plug and play” development of new vaccine.
Has potential utility as a combination vaccine, multi-antigen vaccines, and for vaccines requiring unstable or cytotoxic antigens.
Access
Thermostable and amenable to solid formulations. Positioned to simplify cold-chain logistics and enabling easier distribution.
With applications across multiple market segments
Infectious Diseases
Designed to rapidly respond to new and emerging infectious diseases, and to prevent complex infectious disease.
Chronic Diseases
Potential applications in immuno-therapeutics and allergy treatments.
Animal Health
Potential applications in both companion animal and livestock animal health, as well as biosecurity.
Adjunct Technology
SCV vaccines can also be potentially used as adjunct technology to complement pre-existing therapies or technologies.
Reference cepi.net